|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12345678910111213...4041» |
- dalfampridine / Generic mfg.
Trial primary completion date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Dec 21, 2016
P2, N=25, Active, not recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Jan 2016 --> Nov 2016
- Biomarker, Trial completion: Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension (clinicaltrials.gov) - Dec 16, 2016
P=N/A, N=30, Completed, Sponsor: Louisiana State University Health Sciences Center in New Orleans
Trial primary completion date: Jan 2016 --> Nov 2016 Recruiting --> Completed
- Trial completion: Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis (clinicaltrials.gov) - Dec 15, 2016
P1/2, N=9, Completed, Sponsor: Germans Trias i Pujol Hospital
Recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
P1 data, Trial primary completion date, MRI: A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients (clinicaltrials.gov) - Dec 13, 2016
P1, N=12, Recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- || Trial primary completion date: Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis (clinicaltrials.gov) - Dec 2, 2016
P2, N=158, Recruiting, Sponsor: University of Miami
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- vigabatrin / Generic mfg.
Enrollment change, Trial termination: STARS: Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients (clinicaltrials.gov) - Dec 2, 2016
P4, N=1, Terminated, Sponsor: University of Pennsylvania
Trial primary completion date: Dec 2016 --> Dec 2017 N=12 --> 1 | Recruiting --> Terminated; Was not possible to enroll sufficient number of subjects to draw any worthwhile conclusions from the study.
- | l-methylfolate / Generic mfg.
Trial completion: Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) (clinicaltrials.gov) - Nov 23, 2016
P1, N=38, Completed, Sponsor: University of Iowa
N=12 --> 1 | Recruiting --> Terminated; Was not possible to enroll sufficient number of subjects to draw any worthwhile conclusions from the study. Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Enrollment change: Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (clinicaltrials.gov) - Nov 22, 2016
P2, N=23, Completed, Sponsor: Anders Svenningsson
Active, not recruiting --> Completed Recruiting --> Completed | N=30 --> 23
- dronabinol oral / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Cannabis for Spasticity in Multiple Sclerosis (clinicaltrials.gov) - Nov 16, 2016
P1/2, N=42, Terminated, Sponsor: University of California, Davis
Recruiting --> Completed | N=30 --> 23 N=60 --> 42 | Recruiting --> Terminated | Trial primary completion date: Jan 2013 --> Jul 2017; Unable to complete subject recruitment
- Trial completion, Enrollment change: Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis (clinicaltrials.gov) - Nov 16, 2016
P=N/A, N=226, Completed, Sponsor: Dr. med. Micha Loebermann
N=60 --> 42 | Recruiting --> Terminated | Trial primary completion date: Jan 2013 --> Jul 2017; Unable to complete subject recruitment Recruiting --> Completed | N=400 --> 226
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study (clinicaltrials.gov) - Nov 14, 2016
P2, N=25, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=400 --> 226 Trial primary completion date: Jul 2015 --> Nov 2015
- || Trial primary completion date: Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients (clinicaltrials.gov) - Nov 10, 2016
P1/2, N=100, Active, not recruiting, Sponsor: University of British Columbia
Trial primary completion date: Jul 2015 --> Nov 2015 Trial primary completion date: Jan 2016 --> Sep 2016
- | Biomarker, Trial completion, Trial primary completion date: A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis (clinicaltrials.gov) - Nov 9, 2016
P=N/A, N=49, Completed, Sponsor: John F. Foley, MD
Trial primary completion date: Jan 2016 --> Sep 2016 Recruiting --> Completed | Trial primary completion date: May 2016 --> Oct 2016
- Trial primary completion date: A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=240, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed | Trial primary completion date: May 2016 --> Oct 2016 Trial primary completion date: Feb 2016 --> Nov 2017
- ambrisentan / Generic mfg.
Phase classification: A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma). (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=20, Completed, Sponsor: Stanford University
Trial primary completion date: Feb 2016 --> Nov 2017 Phase classification: P1 --> P=N/A
- Trial completion, Enrollment change: Upper Limbs Intervention in Multiple Sclerosis (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=37, Completed, Sponsor: Universidad de Granada
Phase classification: P1 --> P=N/A Active, not recruiting --> Completed | N=30 --> 37
- Trial completion, Enrollment change: Cognitive Motor Interference Rehabilitation in Persons With Multiple Sclerosis (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=20, Completed, Sponsor: University of Illinois at Urbana-Champaign
Active, not recruiting --> Completed | N=30 --> 37 Recruiting --> Completed | N=30 --> 20
- Trial completion: Computerized Cognition Testing and Cognitive Motor Interference in MS (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=29, Completed, Sponsor: University of Illinois at Urbana-Champaign
Recruiting --> Completed | N=30 --> 20 Recruiting --> Completed
- Trial primary completion date: Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=108, Recruiting, Sponsor: University Hospital, Lille
Recruiting --> Completed Trial primary completion date: Sep 2016 --> Sep 2017
- Trial termination, Trial primary completion date: T and B Cell Responses in Autoimmune Diseases (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=68, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Sep 2016 --> Sep 2017 Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Oct 2015; Lack of enrollment.
- ||||||| Tracleer (bosentan) / J&J, Roche
Trial completion: RAPIDS-2: Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma (clinicaltrials.gov) - Oct 26, 2016
P3, N=188, Completed, Sponsor: Actelion
Active, not recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Oct 2015; Lack of enrollment. No longer recruiting --> Completed
- riluzole / Generic mfg., rasagiline / Generic mfg.
Trial completion: Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Oct 25, 2016
P2, N=252, Completed, Sponsor: University of Ulm
No longer recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=200, Active, not recruiting, Sponsor: University of Ulm
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Dec 2017
- ||| Copaxone 3TW (glatiramer acetate three times a week) / Teva
Trial completion, Trial primary completion date: Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=150, Completed, Sponsor: University at Buffalo
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Dec 2017 Enrolling by invitation --> Completed | Trial primary completion date: Apr 2016 --> Oct 2016
- Enrollment change, Trial termination, Trial primary completion date: Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis (clinicaltrials.gov) - Oct 19, 2016
P=N/A, N=69, Terminated, Sponsor: New York University School of Medicine
Enrolling by invitation --> Completed | Trial primary completion date: Apr 2016 --> Oct 2016 N=160 --> 69 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2016
- dalfampridine / Generic mfg.
Enrollment change: Fampridine Pregnancy Exposure Registry (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=1, Terminated, Sponsor: Biogen
N=160 --> 69 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2016 N=375 --> 1
- Trial primary completion date: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis (clinicaltrials.gov) - Oct 18, 2016
P1, N=20, Active, not recruiting, Sponsor: Tisch Multiple Sclerosis Research Center of New York
N=375 --> 1 Trial primary completion date: Jun 2016 --> Dec 2016
- Trial completion, Trial primary completion date: Effects of Cognitive Behavioural Therapy and Exercise on Stress and Cognitive Deficits in Multiple Sclerosis (clinicaltrials.gov) - Oct 17, 2016
P=N/A, N=173, Completed, Sponsor: Sunnybrook Health Sciences Centre
Trial primary completion date: Jun 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Oct 2016
- |||| Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion, Monotherapy: SELECTED: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 17, 2016
P2, N=410, Completed, Sponsor: Biogen
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Oct 2016 Active, not recruiting --> Completed
- Trial primary completion date: High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases (clinicaltrials.gov) - Oct 14, 2016
P=N/A, N=15, Suspended, Sponsor: Stanford University
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Jun 2017
- Trial completion: Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - Oct 7, 2016
P=N/A, N=911, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jun 2016 --> Jun 2017 Active, not recruiting --> Completed
- Nanocort (liposomal prednisolone) / Galapagos, Enceladus
Clinical: Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS) (clinicaltrials.gov) - Oct 6, 2016
P2, N=15, Terminated, Sponsor: Galapagos NV
Active, not recruiting --> Completed N=90 --> 15 | Suspended --> Terminated | Trial primary completion date: Apr 2012 --> Nov 2011
- Enrollment closed, Trial primary completion date: Power Over Pain (POP) Study (clinicaltrials.gov) - Sep 30, 2016
P=N/A, N=144, Active, not recruiting, Sponsor: University of Washington
N=90 --> 15 | Suspended --> Terminated | Trial primary completion date: Apr 2012 --> Nov 2011 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Feb 2018
- Trial completion, Enrollment change: Functional Electrical Stimulation for People With Multiple Sclerosis Who Experience Foot Drop (clinicaltrials.gov) - Sep 28, 2016
P=N/A, N=15, Completed, Sponsor: Queen Margaret University
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Feb 2018 Recruiting --> Completed | N=10 --> 15
- cyclophosphamide / Generic mfg.
Trial completion: Autologous Stem Cell Transplant for Multiple Sclerosis (clinicaltrials.gov) - Sep 28, 2016
P2, N=24, Completed, Sponsor: Ottawa Hospital Research Institute
Recruiting --> Completed | N=10 --> 15 Active, not recruiting --> Completed
- | C-82 Topical Gel, 1% / PRISM Pharma
Biomarker, Trial completion: Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial (clinicaltrials.gov) - Sep 27, 2016
P1/2, N=17, Completed, Sponsor: Prism Pharma Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change, Trial withdrawal: Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis (clinicaltrials.gov) - Sep 26, 2016
P2, N=0, Withdrawn, Sponsor: Louisiana State University Health Sciences Center in New Orleans
Active, not recruiting --> Completed N=48 --> 0 | Not yet recruiting --> Withdrawn
- Trial completion, Enrollment change, Trial primary completion date: Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Sep 26, 2016
P1, N=40, Completed, Sponsor: Neurogen Brain and Spine Institute
N=48 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed | N=200 --> 40 | Trial primary completion date: Dec 2015 --> Mar 2015
- Catena (idebenone) / Chiesi
Trial primary completion date: Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) (clinicaltrials.gov) - Sep 26, 2016
P1/2, N=85, Active, not recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed | N=200 --> 40 | Trial primary completion date: Dec 2015 --> Mar 2015 Trial primary completion date: Sep 2016 --> Jan 2018
- || Trial primary completion date: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - Sep 23, 2016
P4, N=434, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2016 --> Jan 2018 Trial primary completion date: Jul 2016 --> Oct 2016
- Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial primary completion date: Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients (clinicaltrials.gov) - Sep 22, 2016
P4, N=27, Active, not recruiting, Sponsor: Multiple Sclerosis Center of Northeastern New York
Trial primary completion date: Jul 2016 --> Oct 2016 Trial primary completion date: Jul 2016 --> Dec 2016
- ||| Trial completion, Enrollment change: LARMES: Tear Analysis in the Diagnosis of Multiple Sclerosis (clinicaltrials.gov) - Sep 20, 2016
P=N/A, N=80, Completed, Sponsor: Lille Catholic University
Trial primary completion date: Jul 2016 --> Dec 2016 Active, not recruiting --> Completed | N=100 --> 80
- Trial completion: A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Sep 20, 2016
P1, N=25, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | N=100 --> 80 Active, not recruiting --> Completed
- Enrollment open: Implementing Physical Activity Guidelines for Adults With MS (clinicaltrials.gov) - Sep 16, 2016
P=N/A, N=130, Recruiting, Sponsor: McMaster University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment closed, Trial primary completion date: Mindfulness-based Stress Reduction for Multiple Sclerosis (clinicaltrials.gov) - Sep 14, 2016
P=N/A, N=60, Active, not recruiting, Sponsor: National College of Natural Medicine
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Apr 2017
- Trial primary completion date: Detecting and Addressing Preclinical Disability (clinicaltrials.gov) - Sep 14, 2016
P=N/A, N=148, Active, not recruiting, Sponsor: McMaster University
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Jun 2016 --> Dec 2016
- | Tysabri (natalizumab) / Biogen, Royalty
Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod (clinicaltrials.gov) - Sep 14, 2016
P=N/A, N=25, Completed, Sponsor: University Hospital, Basel, Switzerland
Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Completed | N=40 --> 25 | Trial primary completion date: Dec 2016 --> Aug 2016
- |||| everolimus / Generic mfg.
Trial primary completion date: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Sep 12, 2016
P3, N=365, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=40 --> 25 | Trial primary completion date: Dec 2016 --> Aug 2016 Trial primary completion date: Oct 2016 --> Oct 2017
- |||| Betaseron (IFN-?-1b) / Bayer
Trial completion, Phase classification: Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov) - Sep 8, 2016
P4, N=68, Completed, Sponsor: Bayer
Trial primary completion date: Oct 2016 --> Oct 2017 Active, not recruiting --> Completed | Phase classification: PN/A --> P4
- |||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion: EMR200136-549: Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (clinicaltrials.gov) - Sep 6, 2016
P2, N=80, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed | Phase classification: PN/A --> P4 Active, not recruiting --> Completed